These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 20628902)

  • 1. Adipocytes participate in storage in α-galactosidase deficiency (Fabry disease).
    Hůlková H; Elleder M
    J Inherit Metab Dis; 2010 Dec; 33 Suppl 3(Suppl 3):S297-300. PubMed ID: 20628902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Electron microscopic observations on cultured fibroblasts from Fabry heterozygotes and hemizygotes.
    Wandall A; Hasholt L; Sørensen SA
    Ultrastruct Pathol; 1982; 3(1):51-8. PubMed ID: 6280349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel small insertion mutation, C.1030_1031ins (T) in α-galactosidase A leads to renal variant fabry disease.
    Choi JS; Kim CS; Park JW; Bae EH; Ma SK; Choi YD; Kim GH; Yoo HW; Kim SW
    Ren Fail; 2012; 34(3):390-3. PubMed ID: 22260214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fabry disease in a patient with Turner syndrome.
    Brouns R; Eyskens F; De Boeck K; Ceuterick-de Groote C; Van den Broeck M; Van Broeckhoven C; De Deyn PP
    J Inherit Metab Dis; 2009 Dec; 32 Suppl 1():S45-8. PubMed ID: 19343533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of lysosomal storage disorders on biology of mesenchymal stem cells: Evidences from in vitro silencing of glucocerebrosidase (GBA) and alpha-galactosidase A (GLA) enzymes.
    Squillaro T; Antonucci I; Alessio N; Esposito A; Cipollaro M; Melone MAB; Peluso G; Stuppia L; Galderisi U
    J Cell Physiol; 2017 Dec; 232(12):3454-3467. PubMed ID: 28098348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder.
    Yam GH; Zuber C; Roth J
    FASEB J; 2005 Jan; 19(1):12-8. PubMed ID: 15629890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fabry disease: ultrastructural lectin histochemical analyses of lysosomal deposits.
    Kanda A; Nakao S; Tsuyama S; Murata F; Kanzaki T
    Virchows Arch; 2000 Jan; 436(1):36-42. PubMed ID: 10664160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The D313Y variant in the GLA gene - no evidence of a pathogenic role in Fabry disease.
    Hasholt L; Ballegaard M; Bundgaard H; Christiansen M; Law I; Lund AM; Norremolle A; Krogh Rasmussen A; Ravn K; Tumer Z; Wibrand F; Feldt-Rasmussen U
    Scand J Clin Lab Invest; 2017 Dec; 77(8):617-621. PubMed ID: 29037082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fabry disease. Classic hemizygote and residual alpha-galactosidase A activity.
    Pravata G; Noto G; Arico M
    Int J Dermatol; 1991 May; 30(5):367-9. PubMed ID: 1648549
    [No Abstract]   [Full Text] [Related]  

  • 10. Fabry disease cardiomyopathy: from genes to clinical manifestations.
    Kertész AB; Édes I
    Curr Pharm Biotechnol; 2012 Oct; 13(13):2477-84. PubMed ID: 22280422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel missense mutation (M72V) of alpha-galactosidase gene and its expression product in an atypical Fabry hemizygote.
    Okumiya T; Kawamura O; Itoh K; Kase R; Ishii S; Kamei S; Sakuraba H
    Hum Mutat; 1998; Suppl 1():S213-6. PubMed ID: 9452090
    [No Abstract]   [Full Text] [Related]  

  • 12. Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer.
    Ziegler RJ; Yew NS; Li C; Cherry M; Berthelette P; Romanczuk H; Ioannou YA; Zeidner KM; Desnick RJ; Cheng SH
    Hum Gene Ther; 1999 Jul; 10(10):1667-82. PubMed ID: 10428212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of an Allosteric Binding Site on Human Lysosomal Alpha-Galactosidase Opens the Way to New Pharmacological Chaperones for Fabry Disease.
    Citro V; Peña-García J; den-Haan H; Pérez-Sánchez H; Del Prete R; Liguori L; Cimmaruta C; Lukas J; Cubellis MV; Andreotti G
    PLoS One; 2016; 11(10):e0165463. PubMed ID: 27788225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutant alpha-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin.
    Ishii S; Chang HH; Kawasaki K; Yasuda K; Wu HL; Garman SC; Fan JQ
    Biochem J; 2007 Sep; 406(2):285-95. PubMed ID: 17555407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR/Cas9-based GLA knockout to generate the female Fabry disease human induced pluripotent stem cell line MHHi001-A-15.
    Juchem M; Lehmann N; Behrens YL; Bär C; Thum T; Hoepfner J
    Stem Cell Res; 2024 Sep; 79():103478. PubMed ID: 38905814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzymatic and functional correction along with long-term enzyme secretion from transduced bone marrow hematopoietic stem/progenitor and stromal cells derived from patients with Fabry disease.
    Takenaka T; Hendrickson CS; Tworek DM; Tudor M; Schiffmann R; Brady RO; Medin JA
    Exp Hematol; 1999 Jul; 27(7):1149-59. PubMed ID: 10390190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. α-Galactosidase A knockout mice: progressive organ pathology resembles the type 2 later-onset phenotype of Fabry disease.
    Bangari DS; Ashe KM; Desnick RJ; Maloney C; Lydon J; Piepenhagen P; Budman E; Leonard JP; Cheng SH; Marshall J; Thurberg BL
    Am J Pathol; 2015 Mar; 185(3):651-65. PubMed ID: 25553976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absence of α-galactosidase cross-correction in Fabry heterozygote cultured skin fibroblasts.
    Fuller M; Mellett N; Hein LK; Brooks DA; Meikle PJ
    Mol Genet Metab; 2015 Feb; 114(2):268-73. PubMed ID: 25468650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [alpha-Galactosidase gene mutation and its expression product in Fabry disease (alpha-galactosidase deficiency)].
    Okumiya T; Takata T; Sasaki M; Sakuraba H
    Rinsho Byori; 1997 Feb; 45(2):127-35. PubMed ID: 9120996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. α-galactosidase A deficiency promotes von Willebrand factor secretion in models of Fabry disease.
    Kang JJ; Kaissarian NM; Desch KC; Kelly RJ; Shu L; Bodary PF; Shayman JA
    Kidney Int; 2019 Jan; 95(1):149-159. PubMed ID: 30470436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.